Ypsomed reports positive outcomes from a large, randomized trial of its closed-loop insulin delivery technology during type 1 diabetes pregnancy. The Switzerland-based company’s AiDAPT study demonstrated that hybrid closed-loop therapy significantly improves maternal glycemic control. Pregnant women with type 1 diabetes used the automated insulin delivery system based on the CamDiab CamAPS FX algorithm in […]
CamDiab
FDA approves hybrid closed-loop insulin delivery app from CamDiab
CamDiab announced today that the FDA granted authorization for its CamAPS FX advanced adaptive closed-loop artificial pancreas app. CamAPS FX, an Android app, received approval as an interoperable automated glycemic controller device (iAGC). It helps to manage glucose levels in people with type 1 diabetes, aged two and older, including during pregnancy. The app allows […]
Study highlights benefits of automated insulin delivery for children in UK
A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies. This comes on the heels of a UK NHS initiative to provide tens of thousands of children and adults with type 1 diabetes in the country with an artificial pancreas. The study aimed to assess the efficacy of […]
Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes
Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women. Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study. Ypsomed says […]
Study supports use of CamDiab artificial pancreas in pregnant women with type 1 diabetes
The CamDiab CamAPS FX automated insulin delivery (AID) system produced better outcomes for pregnant women with type 1 diabetes in a clinical study. Medscape reported that data came from the largest randomized controlled trial pitting an AID system against standard insulin delivery in pregnant women with type 1 diabetes. The automated CamAPS FX came out […]
Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK
Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery. Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 […]
The 10 biggest diabetes tech stories from 2022
2022 represented a landmark year for next-generation diabetes tech. Here are the biggest stories from the past year. Some companies picked up major regulatory nods. Others experienced major regulatory setbacks. Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from in the world of diabetes tech, […]
Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe
Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab. Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data. The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries […]
Ypsomed, CamDiab launch first automated insulin dosing system with Abbott FreeStyle Libre 3
Ypsomed announced that its mylife Loop now has authorization to work with the Abbott FreeStyle Libre 3 sensor in Germany. The Ypsomed mylife YpsoPump combines with the CamDiab mylife CamAPS FX algorithm and FreeStyle Libre 3. Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can […]
CGMs, insulin pumps and more: the biggest diabetes news to come out of ATTD 2022
All kinds of technologies were on display at the Advanced Technologies & Treatments for Diabetes (ATTD) conference in Barcelona last week. From continuous glucose monitoring (CGM) to automated insulin delivery, with plenty in between, a number of companies shared positive data for their diabetes offerings. Here are five of the biggest stories to come out […]
